Allergy Therapeutics PLC Update on funding (4149S)
November 06 2023 - 1:00AM
UK Regulatory
TIDMAGY
RNS Number : 4149S
Allergy Therapeutics PLC
06 November 2023
Al l er gy Therapeu tics p lc
(" A l l ergy Ther apeut ics", the "Group" or "C o mpany ")
Update on funding
6 November 2023 Allergy Therapeutics plc (AIM: AGY), the
integrated commercial biotechnology company specialising in allergy
vaccines, today announces a positive update on the Group's working
capital position. Following the release of its unaudited
preliminary results on 27 September 2023 for the year ended 30 June
2023, the Group has continued to work on initiatives to enhance
cost control and manage working capital alongside trading broadly
in line with expectations for the current financial year to date.
As a consequence, the Group has extended its cash runway and now
expects to require additional funding by the end of December
2023.
Since the completion of the subscription and open offer,
announced on 13 October 2023, discussions with certain major
shareholders have progressed. Whilst there are currently no firm
commitments in place to provide further funding, discussions are
continuing positively.
The Pivotal Phase III Grass G306 MATA MPL trial remains on track
to report interim trial results in November 2023.
ENDS
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and Broker)
Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
ICR Consilium
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDKZMGMLKVGFZM
(END) Dow Jones Newswires
November 06, 2023 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024